Australia Oncology Therapeutics Market Report 2022 to 2030

Australia Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Australia Oncology Therapeutics Market will reach a value of $4.6 Bn from $2.2 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in Australia is dominated by a few domestic pharmaceutical companies such as CSL Behring, Mesoblast, and Sirtex Medical. The Oncology Therapeutics Market in Australia is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Australia Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10AUPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Dr. Vishwa Modhia

Buy Now

Australia Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Australia Oncology Therapeutics Market will reach a value of $4.6 Bn from $2.2 Bn in 2022, growing at a CAGR of 9.9% during 2022-30.

Australia is a high-income developed country in Oceania bordering the Indian Ocean and the Southern Pacific Ocean. Cancer is a major cause of illness in Australia, accounting for 18% of the burden of illness endured by Australians and about 9% of health-system expenditure attributed to specific diseases. In Australia, nearly 1 Mn people are either currently or have been diagnosed with cancer.

Cancer survival varies by cancer, but overall cancer survival has increased, with 70% of all cancer patients living at least five years following diagnosis, up from 51% roughly 30 years ago. Personal and behavioural risk factors account for about half (42%) of the cancer burden (for example, smoking and being overweight). Australia's government spends 10.7% of its GDP on healthcare.

Australia Oncology Therapeutics Market Report 2022 to 2030

Market Dynamics

Market Growth Drivers Analysis

Rural and remote Australians had worse health outcomes than urban Australians, with higher rates of smoking, alcohol consumption, physical inactivity, and obesity. External beam radiotherapy accounts for more than 99 % of radiotherapy services invoiced to the MBS in Australia, with a linear accelerator accounting for roughly 97 % of these. Cancer Australia was founded in 2006 by the Australian government to help all Australians stricken by cancer, as well as their relatives and caregivers. To enable substantial advances in cancer research, Minister of Health and Aged Care Mark Butler announced a significant increase in research funding of $5.15 Mn through Cancer Australia's Priority-driven Collaborative Cancer Research Scheme (PDCCRS). These aspects could boost the Australian Oncology Therapeutics Market.

Market restraints

Because of the continent's low population density, administering radiation in Australia presents geographical obstacles. Australia's economy is still heavily reliant on Chinese expenditure. The differences between Australia's federated states are enormous. Effective tobacco control and comprehensive health care have reduced the burden of lung cancer in Australia. However, concerns such as an ageing population, providing equal health care to rural and indigenous people, and smoking abolition continue to be challenged. Australia's reimbursement agency has lagged behind developed-country counterparts in paying for recently approved cancer therapies, revealing problems at the tail end of a system that patients and industry leaders complain is broken. These factors may deter new entrants into the Australian Oncology Therapeutics Market.

Competitive Landscape

Key Players

CSL Behring: CSL Behring is an Australian biopharmaceutical company that develops and produces a range of cancer therapeutics, including immunotherapies and monoclonal antibodies. The company has several innovative cancer drugs that are currently in clinical development
Mesoblast: Mesoblast is an Australian biotechnology company that develops and produces a range of cancer therapeutics, including cell therapies and biologics. The company has several clinical-stage candidates for a range of cancer types, including leukaemia and solid tumours
Sirtex Medical: Sirtex Medical is an Australian medical device company that produces a range of cancer therapeutics, including targeted radiotherapy
Immutep: Immutep is an Australian biotechnology company that develops and produces a range of cancer therapeutics, including immunotherapies and cell therapies

Notable Recent Deals

December 2022: To the successful projects, the Australian Government will give $3.93 Mn through Cancer Australia, while financial partners will contribute $1.21 Mn. The funding partners are the Leukaemia Foundation, Lung Foundation Australia, My Room Children's Cancer Charity Limited, The Kids' Cancer Project, Australian Lions Childhood Cancer Research Foundation, and Can To Foundation.

June 2022: A new cancer treatment has astounded experts with how effectively it performed in a ground-breaking study, practically curing every participant. Dostarlimab, a monoclonal antibody medication approved in the United Kingdom to treat endometrial cancer, outperformed expectations in a trial at New York's Memorial Sloan Kettering Cancer Center. Each of the 18 colorectal cancer patients had gone into remission one year after the experiment concluded, and doctors were allegedly unable to identify any evidence of cancer.

Healthcare Policies and Reimbursement Scenarios

In Australia, the administrative body liable for the endorsement and guideline of restorative items, including malignant growth therapeutics, is the Therapeutic Goods Administration (TGA). The TGA requires clinical preliminary information from all-around planned examinations to help the security and viability of the medication being referred to. In the public medical services framework, the expense of disease therapies, including malignant growth therapeutics, is covered by the Australian Government through the Pharmaceutical Benefits Scheme (PBS). The PBS is a public program that sponsors the expense of many professionally prescribed meds, including disease therapeutics, for Australian residents and qualified guests.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Australia Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
Colorectal Cancer
Gastrointestinal Cancer
Gynecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the Australia Oncology Therapeutics market will reach a value of $4.6 Bn from $2.2 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030.

In Australia, the administrative body liable for the endorsement and guideline of restorative items, including malignant growth therapeutics, is the Therapeutic Goods Administration (TGA).

The Oncology Therapeutics Market in Australia is dominated by a few domestic pharmaceutical companies such as CSL Behring, Mesoblast, and Sirtex Medical.